{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:38:01Z","timestamp":1764333481006,"version":"3.41.2"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Despite their prevalence and potential severity, non-IgE-mediated drug-induced hypersensitivity reactions (DHRs) are under-researched and poorly defined, particularly in children. Presentations range from mild cutaneous reactions to severe systemic diseases, with pathophysiological mechanisms and reliable diagnostic markers not well established. The lack of validated tests often leads to permanent drug restrictions, reliance on second-line drugs, and increased costs. Focusing on recent advancements and areas needing further research, this review aims to enhance children's recognition, diagnosis, and management of non-IgE-mediated DHRs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies have enhanced the understanding of immediate and delayed non-IgE-mediated drug reactions. Key findings include the Mas-related G protein-coupled receptor X2 in mast cells and the identification of HLA alleles linked to severe cutaneous adverse reactions, such as Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Improved diagnostic techniques, including skin testing, show promise in identifying immediate and delayed non-IgE DHRs. Additionally, research highlights the impact of cofactors, drug metabolites, and co-infections on these DHRs and explores potential biomarkers for predicting reaction severity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Non-IgE-mediated DHRs are a significant cause of morbidity and treatment changes in pediatric patients. Recent research underscores their clinical presentations and mechanisms, paving the way for more precise diagnostic and therapeutic strategies to improve patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001395","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T11:42:30Z","timestamp":1725968550000},"page":"674-683","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics"],"prefix":"10.1097","volume":"36","author":[{"given":"Timothy G.","family":"Chow","sequence":"first","affiliation":[{"name":"Division of Allergy and Immunology, Department of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anum F.","family":"Muzaffar","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Alvarez-Arango","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Departments of Medicine and Pharmacology"},{"name":"Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Maryland, Baltimore, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"e13957","DOI":"10.1111\/pai.13957","article-title":"New perspectives on drug allergy in children","volume":"34","author":"Eigenmann","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"e14091","DOI":"10.1111\/pai.14091","article-title":"The importance of clinical history in the diagnosis of drug hypersensitivity in children","volume":"35","author":"Liccioli","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"1931.e2","DOI":"10.1016\/j.jaip.2021.01.010","article-title":"Trends in US emergency department visits for anaphylaxis among infants and toddlers: 2006-2015","volume":"9","author":"Robinson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jaip.2023.01.029","article-title":"Trends and variation in pediatric anaphylaxis care from 2016 to 2022","volume":"11","author":"Dribin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/cea.14125","article-title":"De-labelling of beta-lactam allergy in children","volume":"52","author":"Bernaola","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/all.13848","article-title":"The challenge of de-labeling penicillin allergy","volume":"75","author":"Stone","year":"2020","journal-title":"Allergy"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11882-023-01087-w","article-title":"Use of the electronic health record for monitoring adverse drug reactions","volume":"23","author":"Muzaffar","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"362.e2","DOI":"10.1016\/j.anai.2017.07.009","article-title":"Frequency of self-reported drug allergy: a systematic review and meta-analysis with meta-regression","volume":"119","author":"Sousa-Pinto","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaip.2018.09.003","article-title":"Antibiotic allergy labels in children are associated with adverse clinical outcomes","volume":"7","author":"Lucas","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2022.01.001","article-title":"Pediatric drug allergy","volume":"42","author":"Prosty","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.anai.2022.09.017","article-title":"Confirmation of drug allergy in a general pediatrics outpatient clinic","volume":"129","author":"Capanoglu","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"e13927","DOI":"10.1111\/pai.13927","article-title":"Safety of direct oral provocation in children with mild beta-lactam hypersensitivity reactions","volume":"34","author":"Pachasidchai","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2024.02.019","article-title":"Non\u2013IgE-mediated immediate drug-induced hypersensitivity reactions","volume":"12","author":"Alvarez-Arango","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaip.2022.12.014","article-title":"Allergenic and mas-related G protein-coupled receptor X2-activating properties of drugs: resolving the two","volume":"11","author":"Sabato","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","article-title":"Non-IgE-mediated anaphylaxis","volume":"147","author":"Cianferoni","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.iac.2021.09.011","article-title":"Pathophysiology of immunologic and nonimmunologic systemic reactions including anaphylaxis","volume":"42","author":"Fowler","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Molecular immunology"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0076-6879(03)73010-9","article-title":"The interaction of liposomes with the complement system: in vitro and in vivo assays","volume":"373","author":"Szebeni","year":"2003","journal-title":"Methods Enzymol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaip.2016.10.021","article-title":"Current knowledge and management of hypersensitivity to aspirin and NSAIDs","volume":"5","author":"Laidlaw","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2147\/JAA.S267005","article-title":"NSAID hypersensitivity in the pediatric population: classification and diagnostic strategies","volume":"15","author":"Cavkaytar","year":"2022","journal-title":"J Asthma Allergy"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaip.2022.01.049","article-title":"Aspirin\/NSAID challenge should be performed routinely in patients with self-reported aspirin\/NSAID allergy","volume":"10","author":"White","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1385\/CRIAI:24:2:137","article-title":"Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs","volume":"24","author":"Berkes","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"1225.e6","DOI":"10.1016\/j.jaci.2012.08.007","article-title":"Cutaneous drug reactions","volume":"130","author":"Khan","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents\u2014updated diagnosis, management, and treatment","volume":"3","author":"Galv\u00e3o","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1159\/000515500","article-title":"Evaluation of hypersensitivity reactions in pediatric patients using biological drugs","volume":"182","author":"Yilmaz Topal","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000511458","article-title":"Hypersensitivity to rituximab in children","volume":"106","author":"Liccioli","year":"2021","journal-title":"Pharmacology"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"159.e2","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/pai.13114","article-title":"Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases","volume":"30","author":"Soyer","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000506199","article-title":"Elevated serum tryptase in nonanaphylaxis cases: a concise review","volume":"181","author":"Lee","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/all.14747","article-title":"Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice","volume":"76","author":"Santos","year":"2021","journal-title":"Allergy"},{"key":"R33-20250730","doi-asserted-by":"crossref","DOI":"10.2500\/aap.2021.42.200091","article-title":"Skin testing and drug challenge in the evaluation of drug hypersensitivity reactions","volume":"42","author":"Wolfson","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12016-021-08919-5","article-title":"Road less traveled: drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides","volume":"62","author":"Zhu","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/cea.13850","article-title":"Vancomycin immediate skin responses in vancomycin-na\u00efve subjects","volume":"51","author":"Alvarez-Arango","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"1024.e3","DOI":"10.1016\/j.jaip.2020.09.017","article-title":"Criteria for intradermal skin testing and oral challenge in patients labeled as fluoroquinolone allergic","volume":"9","author":"Krantz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2018.09.022","article-title":"Controversies in drug allergy: in vitro testing","volume":"143","author":"Mayorga","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1111\/all.14213","article-title":"The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: expression and function","volume":"75","author":"Wedi","year":"2020","journal-title":"Allergy"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/all.14252","article-title":"Surface expression of MRGPRX2 on resting basophils: an area of controversy","volume":"75","author":"Sabato","year":"2020","journal-title":"Allergy"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"1026304","DOI":"10.3389\/fimmu.2022.1026304","article-title":"Mas-related G protein-coupled receptor MRGPRX2 in human basophils: expression and functional studies","volume":"13","author":"Toscano","year":"2023","journal-title":"Front Immunol"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.jaip.2022.09.020","article-title":"A review of adverse reactions to biologics used in allergy-immunology practice","volume":"10","author":"Chow","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11882-022-01048-9","article-title":"Adverse reactions to biologic medications used in allergy and immunology diseases","volume":"22","author":"Chow","year":"2022","journal-title":"Curr Allergy Asthma Rep"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11882-023-01064-3","article-title":"Recent updates in understanding NSAID hypersensitivity","volume":"23","author":"Minaldi","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/pai.12915","article-title":"EAACI\/ENDA Position Paper: diagnosis and management of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) in children and adolescents","volume":"29","author":"Kidon","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1016\/j.jaip.2021.04.008","article-title":"Treating through drug-associated exanthems in drug allergy management: current evidence and clinical aspects","volume":"9","author":"Trubiano","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.clindermatol.2017.08.007","article-title":"Cutaneous adverse drug reactions: kids are not just little people","volume":"35","author":"Waldman","year":"2017","journal-title":"Clin Dermatol"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMcp1104080","article-title":"Exanthematous drug eruptions","volume":"366","author":"Stern","year":"2012","journal-title":"New Engl J Med"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaip.2022.11.035","article-title":"The safety of the direct drug provocation test in beta-lactam hypersensitivity in children: a systematic review and meta-analysis","volume":"11","author":"Srisuwatchari","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.clindermatol.2020.06.013","article-title":"Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-related intertriginous and flexural exanthema, and drug-induced lupus","volume":"38","author":"McNamara","year":"2020","journal-title":"Clin Dermatol"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"1351.e1","DOI":"10.1016\/j.jaip.2024.03.006","article-title":"Drugs associated with serum sickness and serum sickness\u2013like reactions: a review of FDA Adverse Event Reporting System (FAERS) data","volume":"12","author":"Surdacki","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaip.2020.08.047","article-title":"Differentiating between b-lactam-induced serum sicknesse like reactions and viral exanthem in children using a graded oral challenge","volume":"9","author":"Delli Colli","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clindermatol.2020.06.014","article-title":"Pediatric drug eruptions","volume":"38","author":"Nguyen","year":"2020","journal-title":"Clin Dermatol"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","article-title":"Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features","volume":"70","author":"Cho","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"R56-20250730","first-page":"309","article-title":"Desensitization to co-trimoxazole in a patient with fixed drug eruption","volume":"18","author":"Patriarca","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R57-20250730","doi-asserted-by":"crossref","first-page":"769.e1","DOI":"10.1016\/j.jaip.2019.07.020","article-title":"Successful desensitization to metronidazole in a patient with generalized fixed drug eruption","volume":"8","author":"Yung","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MOP.0000000000001146","article-title":"Stevens\u2013Johnson syndrome in children","volume":"34","author":"Ramien","year":"2022","journal-title":"Curr Opin Pediatr"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/pde.14446","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature, with a focus on relapsing cases","volume":"38","author":"Afiouni","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"R60-20250730","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R61-20250730","doi-asserted-by":"crossref","first-page":"267.e5","DOI":"10.1016\/j.jaip.2021.07.025","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): series of 49 French pediatric cases","volume":"10","author":"Bedouelle","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R62-20250730","doi-asserted-by":"crossref","first-page":"1155.e5","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R63-20250730","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2024.05.045","article-title":"First-line antituberculosis drug challenge reactions in DRESS in an HIV endemic setting","author":"Porter","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R64-20250730","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pde.14044","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature","volume":"37","author":"Metterle","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"R65-20250730","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R66-20250730","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short-and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R67-20250730","doi-asserted-by":"crossref","first-page":"492","DOI":"10.47102\/annals-acadmedsg.V47N11p492","article-title":"Relapsing course of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by alopecia universalis and vitiligo","volume":"47","author":"Lian","year":"2018","journal-title":"Ann Acad Med Singap"},{"key":"R68-20250730","doi-asserted-by":"crossref","first-page":"811.e4","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R69-20250730","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R70-20250730","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000501518","article-title":"Antibiotic allergy in children: more than just a label","volume":"180","author":"Abrams","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"R71-20250730","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R72-20250730","doi-asserted-by":"crossref","first-page":"289.e4","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R73-20250730","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.anai.2023.01.034","article-title":"Delabeling penicillin allergy in a pediatric primary care clinic","volume":"130","author":"Chow","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R74-20250730","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.acap.2022.05.019","article-title":"Quality improvement to engage general pediatrics in reducing inaccurate penicillin allergy labels","volume":"22","author":"McLaughlin","year":"2022","journal-title":"Acad Pediatr"},{"key":"R75-20250730","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1542\/hpeds.2020-001636","article-title":"A multidisciplinary quality improvement initiative to facilitate penicillin allergy delabeling among hospitalized pediatric patients","volume":"11","author":"Bauer","year":"2021","journal-title":"Hosp Pediatr"},{"key":"R76-20250730","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A three-year-analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi","year":"2010","journal-title":"Eur J Dermatol"},{"key":"R77-20250730","doi-asserted-by":"crossref","first-page":"2010.e4","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in vivo and ex vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R78-20250730","doi-asserted-by":"crossref","first-page":"1287.e1","DOI":"10.1016\/j.jaip.2017.09.004","article-title":"The combined utility of ex vivo IFN-gamma release enzyme-linked immunospot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions","volume":"6","author":"Trubiano","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R79-20250730","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphar.2019.00149","article-title":"A screening test for HLA-B(\u2217)15:02 in a large United States Patient Cohort identifies broader risk of carbamazepine-induced adverse events","volume":"10","author":"Fang","year":"2019","journal-title":"Front Pharmacol"},{"key":"R80-20250730","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jama.2020.25473","article-title":"Race and pharmacogenomics-personalized medicine or misguided practice?","volume":"325","author":"Goodman","year":"2021","journal-title":"JAMA"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:04:09Z","timestamp":1753898649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001395","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"type":"print","value":"1040-8703"},{"type":"electronic","value":"1531-698X"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}